The FDA has recently issued a Warning Letter to a medical device manufacturer for making unauthorized modifications to a previously cleared device under the 510(k) pathway. In a nod to Eddie Rabbitt’s 1981 hit “Step by Step,” the case underscores a critical regulatory principle: while gradual design changes are common in product lifecycle management, they must stay within the scope of the original clearance — or risk regulatory action.

What Happened?

The device at issue was originally cleared by the FDA for a specific medical procedure within a defined timeframe. However, during a recent inspection, FDA investigators found the manufacturer had implemented a design change that altered the physical characteristics of the device — a change not captured in the original 510(k) submission.

As a result:

• The modified device was deemed “adulterated” because it lacked a premarket approval (PMA) or investigational device exemption (IDE).
• It was also “misbranded” for failing to submit a new 510(k) reflecting the design modification.

FDA’s Position on Device Modifications

The FDA’s guidance, “Deciding When to Submit a 510(k) for a Change to an Existing Device,” outlines that a new 510(k) is required if a modification could significantly affect the device’s safety or effectiveness or represents a major change in intended use.

In this case, the agency determined that:

• The physical modification introduced new technological characteristics.
• These characteristics could impact the device’s performance.
• Therefore, the change warranted a new 510(k).

Importantly, these details were not captured in the original 510(k) submission, leading to the enforcement action.

Key Takeaways for Industry

This Warning Letter highlights the need for rigorous internal review when making design or labeling changes to cleared devices:

• Every modification must be assessed: Evaluate whether the change may significantly affect safety or efficacy or alter the intended use.
• Don’t assume incremental changes are low-risk: Multiple small changes can collectively create a significant impact — step by step.
• Document your rationale: If you determine that a new 510(k) is not necessary, prepare a well-documented internal memo outlining your risk-based justification. This may be critical in the event of future FDA inquiry.
• Understand how FDA learns of issues: This enforcement was the result of an inspection, not a competitor complaint — a reminder that compliance must be proactive, not reactive.
• Know the regulations: Refer to 21 C.F.R. § 807.81 and FDA’s guidance to help determine whether your changes require a new submission.

Final Thoughts

The FDA’s recent action is a strong reminder: lifecycle management is not a loophole for avoiding regulatory review. Each design tweak, no matter how small, deserves careful evaluation. Step by step, these changes can tip the balance — potentially triggering regulatory consequences if not properly documented and submitted